The DEA just held its first procedural hearing on cannabis reclassification, although the focus was more on scheduling future sessions.…
The DEA has postponed a key hearing on the reclassification of cannabis. The hearing was initially set for December 2024,…
The average THC content in illegal cannabis in the U.S. is reported at 16%, with DEA data showing a significant…
The DEA plans to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act, recognizing its accepted…
The U.S. FDA and HHS have recommended reclassifying cannabis from Schedule I to Schedule III, citing its low abuse potential…
The Drug Enforcement Administration (DEA) has asserted that it has the final say in the reclassification of cannabis amid discussions…
The DEA plans to significantly increase the production quotas of psychedelic substances such as psilocybin, ibogaine, and cannabis-related compounds like…
The U.S. Department of Health has recommended cannabis be downgraded from Schedule I to Schedule III on the Controlled Substances…
The DEA says two neo-cannabinoids that have recently appeared in various products sold in the US do not meet the…
The U.S. federal agency is currently proposing a new set of rules that would allow the development of scientific research…
